Late-Breaking Abstract Submissions

Key Details and Deadlines

2020 Abstract Submissions

  • Abstract Submission Opened: April 1, 2020 (complete)
  • Abstract Submission Closed: July 17, 2020 (complete)
  • Abstract Notification: Monday, August 31, 2020 (complete)
  • Late-breaking Abstract Submission: September 9 – 16, 2020
  • Download the Abstract Submission guide

NEW: Disclosures for Presenting Authors are REQUIRED in order to submit your abstract. Please be sure to obtain disclosures for your presenting author prior to beginning your submission.

Co-authors will be directly contacted by AASLD in the next several weeks with instructions on how to provide their disclosures.

Questions? Contact education@aasld.org

Late-Breaking Abstract Submission Criteria

Original late-breaking scientific research conducted and submitted after the original abstract deadline will be reviewed for presentation at The Liver Meeting®. Abstracts are considered "late-breaking" if the works meet the following criteria:

  • The research must be new and of sufficient scientific importance to merit special consideration after the standard abstract deadline. Abstracts should describe either large clinical studies or high-impact translational research that could not be completed prior to the original deadline.
  • Clinical studies must be prospective in design. Authors must justify late consideration by documenting the closure date of the study, which must be March 9 or later (12 weeks before the closure of the abstract submitter). Phase 1 trials will be considered for presentation, but only in poster format.
  • Phase 2/3 trials will be considered for presentation in either oral or poster format. Retrospective studies are not eligible for consideration in the late-breaking category.
  • Laboratory-based studies are not typically considered appropriate as late submissions and must be strongly justified. Authors must specify why experiments could not be completed before the standard abstract deadline.
  • Late-breaking abstracts cannot be a revision of an abstract submitted prior to the submission deadline.
  • Late-breaking abstracts must not have been presented, accepted for presentation, or published in any other scientific venue.
  • All late-breaking abstracts must be accompanied by a brief statement from the authors documenting the reason for eligibility in the clinical or laboratory-based category.

General Information

  • Abstracts received after the deadline will not be accepted and incomplete abstracts will be considered ineligible for inclusion.
  • Abstracts must be submitted online through the abstract submission site. No faxed copies, discs, thumb drives, or email submissions will be accepted.
  • An abstract may only be submitted to the Annual Meeting once. Duplicate abstracts (reporting the same data) that are submitted under a different author will be administratively withdrawn.
  • To submit an abstract, there is a nonrefundable fee of $300. Authors can pay by VISA®, MasterCard®, American Express®, or DISCOVER®; your credit card will be processed by AASLD. Please be sure to list the current expiration date of your credit card.
  • Abstracts will not be considered for publication and/or presentation unless payment is provided. No checks or purchase orders will be accepted.
  • Case reports or novel clinical observations can provide new insight into clinical phenotypes or pathogenesis of the disease. Case reports are not frequently submitted to The Liver Meeting® but authors who so choose may submit one using the same guidelines outlined below for standard abstract submission. Case reports will be scored and ranked by the same review team that scores abstract submissions for the category and descriptor selected by the submitting author.

Formatting / Submission Instructions

Title
  • The title should be brief, but long enough to clearly identify the nature of the study. Omit author degrees, titles, and institutional appointments.
  • Do not include authors in the title. Abstracts containing authors in the title will be administratively withdrawn.
  • Authors must be entered in the abstract submission process.
Authors
  • Indicate the name and location of the institution where the work was done.
  • If an author's name appears on more than one abstract, it must be identical on each abstract.
  • Be sure to include the correct email address for each author upon submission, as this is the only way AASLD will contact authors. Authors will not be able to make changes to any author information past the submission deadline.
  • Be sure to include the correct email address for each author upon submission, as this is the only way AASLD will contact authors. Authors will not be able to make changes to any author information past the submission deadline.
  • Presenting authors and co-authors will receive all notifications and communications related to the accepted abstract(s). Please note AASLD is not responsible for communication between authors. Authors should remain in communication about the status of their abstract(s), disclosures, presentation details, and all other information regarding their abstract(s).
Author Disclosure

By submitting an abstract to be considered for presentation at the Annual Meeting, you agree to comply with AASLD’s Disclosure Policy and the ACCME Standards for Commercial Support. Additionally:

  • Disclosures will be collected from presenting authors at the time of abstract submission.
  • Presenting authors must provide financial disclosures to be considered for inclusion at The Liver Meeting®. If disclosures are not received by the deadline provided in the acceptance notice, the work will be withdrawn from the meeting.
  • Author disclosure of potential conflicts with a commercial interest, for all authors, must be disclosed. (A commercial interest is defined as any entity developing, producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.) Any potential conflict will be identified and managed according to ACCME guidelines.
Abstract Body

The body of the abstract must include the following sections:

  • Background: summarize the purpose, scope, and objectives of the study or research.
  • Methods: describe the methods used to measure your study/research.
  • Results: A summary of the results obtained.
  • Conclusion: A statement of conclusions reached in your study or research. Do not simply state "The results will be discussed." (Abstracts will not be considered for presentation if this statement is made.)
Abstract Size
  • The abstract size is limited to 2,500 characters in the abstract body (including spaces), with an option of up to one image for inclusion in addition to the 2500 characters.
  • Please do not include more than one table or graphic, limited in size to 2" height by 3" width.
Abbreviations
  • Abbreviations should conform to the recommendations made by the IUB Committee of Editors on Biochemical Journals.
  • Use abbreviations in parentheses after the full word the first time it appears. Use no more than three nonstandard abbreviations.
Category and Subcategory
  • Before you submit, review the list of Categories and Subcategories.
  • During the submission process (Step 2) you will be prompted to select a category that best characterizes your research, along with a matching subcategory. These categories will be used to classify abstracts for publication and review.
  • The Scientific Program Committee reserve the right to re-categorize any abstract as deemed appropriate.
Content
  • Presentations must give a balanced view of therapeutic options. Brand names of pharmaceuticals and trade names of medical devices should not be used in the title or body of the abstract. The use of generic names will contribute to impartiality.
  • The Scientific Program Committee reserves the right to change the abstract if they feel that the use of a trade name may be mistaken for commercial propaganda and may replace proprietary names with generic names. In addition, logos representing a commercial interest will be removed prior to the presentation.
  • If the session material or content includes trade names, where available trade names from several companies should be used, not just trade names from a single company.
Drug Names
  • Drug products mentioned in the abstract should be identified by their nonproprietary (i.e. generic) name only.
  • Do not capitalize on nonproprietary names.

Additional Information and Embargo Policy

Notifications
  • Abstract selection notifications will be sent to all authors on August 3, 2020.
  • Late-breaking Abstract selection notifications will be sent in early October.
Withdrawal Requests

The deadline for requests for withdrawal of an abstract will be included in the selection notification sent on August 3. Requests for withdrawal of an abstract made after the deadline stated in the notification will not be considered. This deadline does not apply to late-breaking abstracts.

Revisions

All abstracts will be published with the information provided before the submission deadline. As such:

  • All authors are strongly encouraged to log into the system and review all abstract details (including title, author names and institutions, and abstract data) before the submission deadline to ensure the accuracy of all information provided at the time of submission.
  • Abstract revisions, including the addition or removal of author names, institution changes, and general updates will not be permitted after the submission deadline. This rule is strictly enforced. This deadline does not apply to late-breaking abstracts.
Awards
  • Abstract Award applications are included in the abstract submission process. Applications for The Liver Meeting® 2020 Abstract Awards are accepted during the regular abstract submission period. This does not apply to late-breaking abstracts.
  • For more information Abstract Awards and reimbursement policies, visit Travel and Memorial awards, or send an email to awards@aasld.org.
Ethics Policy

The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD meetings or journals.

  • For reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials.
  • HEPATOLOGY will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.
  • In studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).
Embargo Policy
  • Accepted abstracts are made available to the public on the AASLD website in early October, and are published in the October supplement of HEPATOLOGY.
  • Late-breaking abstracts will be available on the AASLD website and the online planner of The Liver Meeting® app November 1 at 10:00 am ET and are published in the December issue of HEPATOLOGY.
  • Abstract information may not be released until they appear on the AASLD website.
  • Review the Embargo Policy for additional information.
Meeting Registration and Attendance
  • All oral abstract and poster presenters are required to register and attend the Annual Meeting. Presenters who fail to arrange for an alternate presenter or fail to notify AASLD staff of withdrawal and do not present their oral abstract(s) and/or poster(s) at the Meeting may be administratively withdrawn from future AASLD conferences.
  • Expenses associated with the submission, registration, travel, and other costs related to the presentation of the abstract are the sole responsibility of the presenting author. Authors submitting multiple abstracts must select a co-author.
  • Learn more about registration, exhibitors, and create your visa letter.
Official Language

All presentations will be conducted in English. Oral abstracts must be presented by an author who understands and speaks English well.

Previous Presentation of Abstracts
  • An abstract is ineligible for consideration if it reports work that has been published or accepted for publication prior to the October issue of HEPATOLOGY, or it reports work that has been accepted for presentation in the United States prior to the abstract submission deadline.
  • Abstracts will be considered for presentation if they were presented at national meetings in countries outside the United States.
Scoring Criteria
  • Abstracts are scored by a minimum of four reviewers for each category and ranked according to a numerical score. Reviewers with conflicts are required to recuse themselves from the review process.
  • Abstracts are ranked within the category selected at the time of submission, although reviewers may re-categorize an abstract, based on the content.
  • Posters of Distinction are considered to be particularly noteworthy and represent the top 10% of all accepted poster presentations.
  • Abstracts reporting incomplete data at the time of submission will receive a lower priority score. In such circumstances, consideration should be given to submitting the complete data as a "late-breaking abstract," if available.
Selection Process
  • All abstracts are blinded, peer-reviewed, and ranked on the basis of scientific merit by experts in the category selected. The Scientific Program Committee uses these rankings to develop the scientific sessions.
  • Abstracts are assigned to plenary, parallel, or poster sessions based on abstract rank, and suitability of the abstract content within the session topic or category.
  • Authors will have the ability to choose Oral or Poster Only in Step 2 of the abstract submission process.
  • Original research not completed before the abstract deadline may be eligible for submission as a late-breaking abstract.